Compound ID | 1876
Synonym(s): RPX7009
Class: Beta-lactamase inhibitor (heterocyclic boron)
Details of activity: | Binds reversibly to beta-lactamases with a focus on class A enzymes, especially KPC enzymes. Fixed combination with meropenem |
Combined with other compounds: | Yes |
Description: | Synthetic compound. 2017 approved in fixed combination with meropenem (Vabomere, Vaborem) |
Institute where first reported: | Rempex Pharmaceuticals, Melinta TherapeuticsMenarini |
Year first mentioned: | 2013 |
Highest developmental phase: | Approved by FDA in 2017 |
Development status: | Approved |
Chemical structure(s): | |||||||||||
|
|